Consistent data matters. Prolaris® is the best answer for your prostate cancer patients. Submit the form below to learn why.

September 16, 2022

Prolaris: Your NEW ADT decision tool

When it comes to treating NCCN intermediate- and high-risk prostate cancer, it can be challenging to know which patients could truly benefit from the use of ADT (Androgen Deprivation Therapy) + RT (Radiation Therapy). The Prolaris white paper tells our exclusive story of consistent data across our validation and utility studies; giving you confidence to choose Prolaris when you need to know which patients would have little to no benefit from ADT.

Request Prolaris White Paper

If for some reason you don’t receive the email with your white paper download, make sure to check your junk folder.

Physician First Name

Physician Last Name

NPI Number

Specialty

Zip Code

How can we help?

Hidden Fields

Google Account ID

Web_Form_URL__c

Google_Client_Id__c

GCLID

UTM Medium

UTM Source

UTM Campaign

UTM Content

UTM Term

AE_Email

AE_First_Name

AE_Last_Name

Myriad needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.